Published in Blood on March 15, 1995
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood (2008) 6.39
From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer (2009) 4.15
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol (2009) 2.34
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood (2008) 2.22
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood (2011) 2.04
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med (2007) 2.00
Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood (2008) 1.93
Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood (2008) 1.87
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood (2009) 1.75
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant (2010) 1.72
Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol (2009) 1.64
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. Leuk Lymphoma (2009) 1.59
Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood (2011) 1.44
The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia. Cancer (2011) 1.42
Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood (2012) 1.41
Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci U S A (2004) 1.40
Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. J Transl Med (2009) 1.35
Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features. Leukemia (2012) 1.24
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol Cancer (2010) 1.18
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer (2008) 1.18
Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood (2006) 1.15
Update in the management of chronic lymphocytic leukemia. J Hematol Oncol (2009) 1.14
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol (2009) 1.13
Fludarabine in the treatment of chronic lymphocytic leukemia: a review. Ther Clin Risk Manag (2009) 1.12
Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL. Leukemia (2011) 1.07
Loss of p53 and altered miR15-a/16-1MCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells. Leukemia (2013) 1.04
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood (2009) 1.03
Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. Haematologica (2009) 1.01
Refractory chronic lymphocytic leukemia--new therapeutic strategies. Oncotarget (2010) 1.00
Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders. Proc Natl Acad Sci U S A (1996) 1.00
Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome). Am J Pathol (2002) 1.00
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. Clin Cancer Res (2009) 0.98
Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go. Biomed Res Int (2014) 0.98
Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia. J Mol Diagn (2008) 0.97
Identification of networks of co-occurring, tumor-related DNA copy number changes using a genome-wide scoring approach. PLoS Comput Biol (2010) 0.97
High-level DNA amplifications are common genetic aberrations in B-cell neoplasms. Am J Pathol (1997) 0.96
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. Leuk Lymphoma (2012) 0.96
Antibody therapy for chronic lymphocytic leukemia. Semin Hematol (2008) 0.95
Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis. Br J Haematol (2013) 0.94
Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells. PLoS One (2011) 0.94
The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia. Oncogene (2012) 0.93
Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia (2013) 0.92
Loss of functional cell surface transforming growth factor beta (TGF-beta) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (1997) 0.92
Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population. BMC Cancer (2010) 0.90
Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. Leuk Lymphoma (2011) 0.90
The implications of an incidental chronic lymphocytic leukaemia in a resection specimen for colorectal adenocarcinoma. World J Surg Oncol (2007) 0.88
Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. BMC Med Genomics (2013) 0.87
The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer (2016) 0.86
The emerging role of Twist proteins in hematopoietic cells and hematological malignancies. Blood Cancer J (2014) 0.84
Predicting survival in head and neck squamous cell carcinoma from TP53 mutation. Hum Genet (2014) 0.84
AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells. Eur J Immunol (2014) 0.84
LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients. Blood (2011) 0.83
Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease. Br J Haematol (2009) 0.83
Loss of chromosome 11q21-23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma. Br J Cancer (2001) 0.83
Case report: rare case of infiltration of small lymphocytic B-cell lymphoma in the thyroid gland of female patient with B-cell chronic lymphocytic leukemia (CLL-B/SLL-B). Thyroid Res (2013) 0.82
Trichostatin A effectively induces apoptosis in chronic lymphocytic leukemia cells via inhibition of Wnt signaling and histone deacetylation. J Cancer Res Clin Oncol (2014) 0.82
Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure? Br J Cancer (1998) 0.81
lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome. Blood Cancer J (2016) 0.81
Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia. Genes Chromosomes Cancer (2015) 0.80
Advances in treating chronic lymphocytic leukemia. F1000Prime Rep (2014) 0.79
Omics Screening for Pharmaceutical Efficacy and Safety in Clinical Practice. J Pharmacogenomics Pharmacoproteomics (2012) 0.79
An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases. Oncogene (2016) 0.78
Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia? Per Med (2013) 0.78
A new phosphorylated form of Ku70 identified in resistant leukemic cells confers fast but unfaithful DNA repair in cancer cell lines. Oncotarget (2015) 0.78
The spectrum of genetic defects in chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis (2012) 0.78
To treat or not to treat: metabolomics reveals biomarkers for treatment indication in chronic lymphocytic leukaemia patients. Oncotarget (2016) 0.78
Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells. Haematologica (2011) 0.77
FISH Analysis for del6q21 and del17p13 in B-cell Chronic Lymphocytic Leukemia in Iranians. Iran Red Crescent Med J (2013) 0.77
De novo deletion 17p13.1 as a predictor for disease progression in chronic lymphocytic leukemia. Clin Exp Med (2014) 0.77
First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. Onco Targets Ther (2010) 0.77
Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma. Br J Cancer (2010) 0.76
Jumping translocations, a novel finding in chronic lymphocytic leukaemia. Br J Haematol (2015) 0.76
Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification. Cell Death Dis (2015) 0.76
Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice. Community Oncol (2012) 0.76
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. J Hematol Oncol (2013) 0.76
Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL). Biologics (2008) 0.75
The genome of chemorefractory chronic lymphocytic leukemia reveals frequent mutations of NOTCH1 and SF3B1. Leuk Suppl (2012) 0.75
Novel targeted treatment strategies for refractory chronic lymphocytic leukaemia. Ther Adv Hematol (2011) 0.75
Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy. Mediterr J Hematol Infect Dis (2016) 0.75
Allogeneic hematopoietic cell transplantation in the treatment of chronic lymphocytic leukemia: why and when? Mediterr J Hematol Infect Dis (2010) 0.75
Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas. Br J Cancer (2001) 0.75
Chronic lymphocytic leukemia: treatment of relapse. Leuk Suppl (2012) 0.75
Reevaluation of ATR signaling in primary resting chronic lymphocytic leukemia cells: evidence for pro-survival or pro-apoptotic function. Oncotarget (2017) 0.75
Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. Mod Pathol (2017) 0.75
Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China. Chin J Cancer Res (2017) 0.75
Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med (2000) 16.30
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (2010) 13.59
Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer (1997) 8.27
Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 3.46
Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev (1997) 3.02
stevor and rif are Plasmodium falciparum multicopy gene families which potentially encode variant antigens. Mol Biochem Parasitol (1998) 2.58
IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol (1999) 2.58
Generation of superoxide (O2-.) from alveolar macrophages exposed to asbestiform and nonfibrous particles. Cancer Res (1987) 2.26
Active and inactive genes localize preferentially in the periphery of chromosome territories. J Cell Biol (1996) 2.25
The dissociation of discriminative and conditioned reinforcing functions of stimuli with changes in deprivation. J Exp Anal Behav (1968) 2.24
Are deprivation indicators a proxy for morbidity? A comparison of the prevalence of arthritis, depression, dyspepsia, obesity and respiratory symptoms with unemployment rates and Jarman scores. J Public Health Med (1993) 2.22
Origin of nanomechanical cantilever motion generated from biomolecular interactions. Proc Natl Acad Sci U S A (2001) 2.22
Portosystemic shunting and persistent fetal vascular structures in aryl hydrocarbon receptor-deficient mice. Proc Natl Acad Sci U S A (2000) 2.22
Polymorphism in ospC gene of Borrelia burgdorferi and immunoreactivity of OspC protein: implications for taxonomy and for use of OspC protein as a diagnostic antigen. J Clin Microbiol (1993) 2.21
Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res (2000) 2.09
Effects of sleep and circadian rhythm on human circulating immune cells. J Immunol (1997) 2.08
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia (2004) 2.08
Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med (1998) 2.05
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol (2012) 2.03
Litigation against the emergency physician: common features in cases of missed myocardial infarction. Ann Emerg Med (1989) 1.99
Is use of hospital services a proxy for morbidity? A small area comparison of the prevalence of arthritis, depression, dyspepsia, obesity, and respiratory disease with inpatient admission rates for these disorders in England. J Epidemiol Community Health (1994) 1.97
Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2011) 1.88
Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood (1996) 1.85
European principles of haemophilia care. Haemophilia (2008) 1.84
Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ (2008) 1.84
Molecular characterization of a carbon transporter in plastids from heterotrophic tissues: the glucose 6-phosphate/phosphate antiporter. Plant Cell (1998) 1.82
Evolution of the Borrelia burgdorferi outer surface protein OspC. J Bacteriol (1995) 1.81
Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol (2009) 1.73
Transcriptional termination signals for RNA polymerase II in fission yeast. EMBO J (1997) 1.72
Quantitative analysis of comparative genomic hybridization. Cytometry (1995) 1.72
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia (2005) 1.72
Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia (2006) 1.70
Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab (1998) 1.70
B-cell neoplasia associated gene with multiple splicing (BCMS): the candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions. Hum Mol Genet (2001) 1.70
11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood (1997) 1.69
Sex pheromones of two Asian moths (Creatonotos transiens, C. gangis; Lepidoptera--Arctiidae): behavior, morphology, chemistry and electrophysiology. Exp Biol (1986) 1.69
Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol (2001) 1.68
Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res (1998) 1.68
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia (2012) 1.68
ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia (2007) 1.64
Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization. Cancer Res (1996) 1.63
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol (2004) 1.62
Sepsis evaluations in hospitalized infants with bronchiolitis. Pediatr Infect Dis J (1998) 1.61
Laparoscopic restorative proctocolectomy. Br J Surg (2005) 1.60
Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer (2005) 1.59
Evidence for human meiotic recombination interference obtained through construction of a short tandem repeat-polymorphism linkage map of chromosome 19. Am J Hum Genet (1993) 1.57
Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood (1999) 1.55
Unusual combination of congenital heart defects in an infant with Noonan syndrome. Pediatr Cardiol (1995) 1.54
Detection of Borrelia burgdorferi DNA in urine samples and cerebrospinal fluid samples from patients with early and late Lyme neuroborreliosis by polymerase chain reaction. J Clin Microbiol (1992) 1.54
Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia (2010) 1.51
High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res (2001) 1.51
High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1-infected children. Blood (1994) 1.50
S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol (1999) 1.49
Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. J Thromb Haemost (2008) 1.48
The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia. Leukemia (2006) 1.47
Assessment of ketorolac as an adjuvant to fentanyl patient-controlled epidural analgesia after radical retropubic prostatectomy. Anesthesiology (1993) 1.47
Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci U S A (2000) 1.46
Activation of the CD95 (APO-1/Fas) system in T cells from human immunodeficiency virus type-1-infected children. Blood (1996) 1.46
Comparison of standard endoscopic submucosal dissection (ESD) versus an optimized ESD technique for the colon: an animal study. Endoscopy (2009) 1.44
Comparison of in vitro culture and polymerase chain reaction for detection of Borrelia burgdorferi in tissue from experimentally infected animals. J Clin Microbiol (1991) 1.43
The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia (2007) 1.42
Minimal sizes of deletions detected by comparative genomic hybridization. Genes Chromosomes Cancer (1998) 1.42
Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia (2010) 1.41
Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up. Haemophilia (2007) 1.40
A new measure for distress during child sexual abuse examinations: the genital examination distress scale. Child Abuse Negl (1999) 1.40
A case-control study on the psychological aspects and coping in haemophilic patients. Haemophilia (2004) 1.39
Pyogranulomatous myocarditis due to Staphylococcus aureus septicaemia in two harbour porpoises (Phocoena phocoena). Vet Rec (2002) 1.39
Genomic imbalances are rare in hairy cell leukemia. Genes Chromosomes Cancer (1999) 1.39
[Argon plasma surgery (APC) in the upper aerodigestive tract. Initial results]. HNO (1998) 1.39
Morphine antagonises action of prostaglandin in neuroblastoma and neuroblastoma times glioma hybrid cells. Nature (1975) 1.38
Direct interaction between Shc and the platelet-derived growth factor beta-receptor. J Biol Chem (1994) 1.37
Bone lesions in early syphilis detected by bone scintigraphy. Br J Vener Dis (1984) 1.35
Construction and characterization of a Plasmodium vivax genomic library in yeast artificial chromosomes. Genomics (1997) 1.34
Sequence analysis and protein import studies of an outer chloroplast envelope polypeptide. Proc Natl Acad Sci U S A (1990) 1.33
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost (2008) 1.29
Expression of the functional mature chloroplast triose phosphate translocator in yeast internal membranes and purification of the histidine-tagged protein by a single metal-affinity chromatography step. Proc Natl Acad Sci U S A (1993) 1.28
Intersection of group I CD1 molecules and mycobacteria in different intracellular compartments of dendritic cells. J Immunol (2000) 1.27
Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant (2005) 1.27
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia (2012) 1.27
Class II correction in patients treated with class II elastics and with fixed functional appliances: a comparative study. Am J Orthod Dentofacial Orthop (2000) 1.26
High resolution BrainPET combined with simultaneous MRI. Nuklearmedizin (2011) 1.26
Efficacy of an oral vaccinia-rabies glycoprotein recombinant vaccine in controlling epidemic raccoon rabies in New Jersey. J Wildl Dis (1998) 1.26
Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood (1996) 1.26
Factors affecting postoperative mortality of patients with displaced femoral neck fracture. Injury (2006) 1.25
Peptide-based OspC enzyme-linked immunosorbent assay for serodiagnosis of Lyme borreliosis. J Clin Microbiol (1998) 1.25
Metastasis-associated Mts1 (S100A4) protein modulates protein kinase C phosphorylation of the heavy chain of nonmuscle myosin. J Biol Chem (1998) 1.25
High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia (2005) 1.24
Borrelia burgdorferi-specific intrathecal antibody production in neuroborreliosis: a follow-up study. Neurology (1993) 1.23
CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. Int J Cancer (2001) 1.23